Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osimertinib + pralsetinib
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of osimertinib (a third-generation EGFR tyrosine kinase inhibitor) and pralsetinib (a selective RET tyrosine kinase inhibitor). This combination is primarily used to overcome resistance to osimertinib monotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients who have acquired RET fusions, particularly ANK3-RET fusion. The combination has demonstrated durable responses exceeding 12 months in clinical cases, even with dose adjustments to manage overlapping toxicities.
02
Targets
JAK2 (Janus kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)RET (Rearranged during transfection receptor tyrosine kinase)NTRK1 (Tropomyosin-related receptor kinase A)FLT3 (Fms related receptor tyrosine kinase 3)PDGFRB (Platelet-derived growth factor receptor beta)JAK1 (Janus kinase 1)NTRK3 (Tropomyosin receptor kinase C)FGFR2 (Keratinocyte growth factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)DDR1 (Discoidin domain receptor 1)
Beyond the preview
Go deeper on osimertinib + pralsetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osimertinib + pralsetinib.